It combines the psychedelic compound Ibogaine with Palmitoylethanolamide, which is a member of the N-Acylethanolamines family. It aims to improve the safety and efficacy of Ibogaine-based treatments.
Under the collaboration, SciSparc and Clearmind are researching combination therapies that integrate psychedelic molecules with the N-acylethanolamines family, including Palmitoylethanolamide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results